Free Trial
OTCMKTS:BNXTF

BioNxt Solutions Q4 2025 Earnings Report

BioNxt Solutions logo
$0.27 0.00 (0.00%)
As of 10/2/2026

BioNxt Solutions EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioNxt Solutions Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioNxt Solutions Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BioNxt Solutions Earnings Headlines

The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
BioNxt Solutions Inc.
See More BioNxt Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNxt Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNxt Solutions and other key companies, straight to your email.

About BioNxt Solutions

BioNxt Solutions (OTCMKTS:BNXTF) is a biotechnology company focused on developing pharmaceutical and drug-delivery technologies. Its work centers on alternative dosage forms designed to improve the administration, absorption, and convenience of medicines, including oral dissolvable and sublingual films, transdermal systems, and other novel delivery platforms.

The company’s development activities have included pharmaceutical products and delivery systems targeting areas such as neurological disorders and other medical conditions. BioNxt has also pursued the development and commercialization of proprietary formulations and related technologies through partnerships and operating activities in North America and Europe, including Germany.

BioNxt Solutions was formerly known as XPhyto Therapeutics Corp. and adopted its current name as it focused more directly on pharmaceutical development and drug-delivery solutions. The company is headquartered in Vancouver, British Columbia, and its leadership has included Chief Executive Officer Hugh Rogers.

View BioNxt Solutions Profile